GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

We had a pretty good chat about it a month ago.
I agree that this could come back to the front burner.
I thought Jesse's remark about how the locus of tissue
damage exceeded that of actual ischemia was clearly
important.

Dew mentioned that the heparin fiasco may have adjusted
some attitudes at the FDA. Just how much of our initial
misadventure re CABG was medical/legal/ethical/political
is not clear to me but I believe the medical part got
short shrift and that might well be revisited, perhaps soon.

This isn't really content, I'm just jacking my jaws saying
I'll second that, especially the part about $100M being a
very conservative lower bound and several $B reasonable in
the best case.

Assuming we survive. I'm very much convinced that AT was
the proper avenue to birth our tech, and that we will see
continued good news from the clinic re its therapeutic scope.
I might be fingering my rosary mounting the gallows--it's hard
not to--but I think your intuition, that CABG will figure in
our news flow over say the next two years, is right where
mine is.

Your post reminds me again that AT's heparin affinity is
strongly conditioned by chain length, so that we have to be
careful about speaking/reading about "heparin" in a generic
sense, at least when tossing numbers around. The wiki article
explains this angle very well.